Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check29 days agoChange DetectedA site-wide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.SummaryDifference0.4%

- Check36 days agoChange DetectedThe footer revision label was updated from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check43 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page history shows a new site revision label v3.7.0, replacing the previous v3.6.6. This indicates a system update to the page rendering and history tracking, not a change to study data or content.SummaryDifference0.1%

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.